News >

Immunotherapy Spearheads Progress in Small Cell Lung Cancer

Caroline Seymour
Published: Thursday, Oct 31, 2019

W. Victoria Lai, MD, medical oncologist at Memorial Sloan Kettering Cancer

W. Victoria Lai, MD

The addition of immunotherapy to standard chemotherapy has resulted in an overall survival (OS) advantage in patients with newly diagnosed, extensive-stage small cell lung cancer (ES-SCLC), shifting not only the frontline standard but potentially second-line treatment as well, said W. Victoria Lai, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication